Preparation & evaluation of Topical Rosuvastatin & Melatonin vs placebo in Patients with Mild to Moderate Plaque Psoriasis
Phase 2
Recruiting
- Conditions
- Psoriasis.Psoriasis
- Registration Number
- IRCT20190810044500N16
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 51
Inclusion Criteria
Patients 18 years and older
Less than 10% body surface area (BSA)
Exclusion Criteria
Pregnancy
Sensitivity to cream components
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Psoriasis Area Severity Index. Timepoint: Weeks 0, 4, 8. Method of measurement: Score 0_72.
- Secondary Outcome Measures
Name Time Method Dermatological Sum Score (DSS). Timepoint: Weeks 0,4,8. Method of measurement: Based on a scale of 4 points (0: absent,1: mild, 2: moderate, 3: severe).;Dermatology Life Quality Index (DLQI). Timepoint: weeks 0,4,8. Method of measurement: Based on the questionnaire.